These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 37217940)

  • 1. Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trials.
    Purwar R; Ranjan R; Pal M; Upadhyay SK; Kumar T; Pandey M
    World J Surg Oncol; 2023 May; 21(1):157. PubMed ID: 37217940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis.
    Batalini F; DaSilva LL; Campoverde L; Comini ACM; Carvalho BM; Nogueira W; Silveira H; Ernst BJ; Mina LA
    Chin Clin Oncol; 2023 Jun; 12(3):21. PubMed ID: 37211773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
    Lee CK; Friedlander ML; Tjokrowidjaja A; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Bloomfield R; Goble S; Wang P; Glasspool RM; Scott CL;
    Cancer; 2021 Jul; 127(14):2432-2441. PubMed ID: 33740262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
    Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
    Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis.
    Li Y
    J Obstet Gynaecol; 2023 Dec; 43(1):2171282. PubMed ID: 36729640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials.
    Baradács I; Teutsch B; Váradi A; Bilá A; Vincze Á; Hegyi P; Fazekas T; Komoróczy B; Nyirády P; Ács N; Bánhidy F; Lintner B
    J Ovarian Res; 2024 Feb; 17(1):53. PubMed ID: 38409030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis.
    Gulia S; Kannan S; Ghosh J; Rath S; Maheshwari A; Gupta S
    ESMO Open; 2022 Oct; 7(5):100558. PubMed ID: 36007449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
    Swisher EM; Aghajanian C; O'Malley DM; Fleming GF; Kaufmann SH; Levine DA; Birrer MJ; Moore KN; Spirtos NM; Shahin MS; Reid TJ; Friedlander M; Steffensen KD; Okamoto A; Sehgal V; Ansell PJ; Dinh MH; Bookman MA; Coleman RL
    Gynecol Oncol; 2022 Feb; 164(2):245-253. PubMed ID: 34906376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2023; 23(5):1-188. PubMed ID: 37637244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status.
    Tomao F; Bardhi E; Di Pinto A; Sassu CM; Biagioli E; Petrella MC; Palaia I; Muzii L; Colombo N; Panici PB
    Cancer Treat Rev; 2019 Nov; 80():101909. PubMed ID: 31629204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: a meta-analysis.
    Lin Q; Liu W; Xu S; Shang H; Li J; Guo Y; Tong J
    BJOG; 2021 Feb; 128(3):485-493. PubMed ID: 32654312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials.
    Shao F; Liu J; Duan Y; Li L; Liu L; Zhang C; He S
    Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32096544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.
    Bartoletti M; Pelizzari G; Gerratana L; Bortot L; Lombardi D; Nicoloso M; Scalone S; Giorda G; Baldassarre G; Sorio R; Puglisi F
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis.
    Suh YJ; Lee B; Kim K; Jeong Y; Choi HY; Hwang SO; Kim YB
    BMC Cancer; 2022 Mar; 22(1):346. PubMed ID: 35354431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of poly (ADP-ribose) polymerase inhibitors (PARPis) as maintenance therapy for newly-diagnosed and platinum-sensitive recurrent ovarian cancer with
    Zhou S; Jiang Y; Luo C; Yuan L
    Expert Rev Anticancer Ther; 2024; 24(1-2):59-69. PubMed ID: 38174379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of PARP inhibitors in homologous recombination proficient ovarian cancer: meta-analysis.
    Skelin M; Šarčević D; Lešin Gaćina D; Mucalo I; Dilber I; Javor E
    J Chemother; 2023 Apr; 35(2):150-157. PubMed ID: 35550005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.
    Cadoo K; Simpkins F; Mathews C; Liu YL; Provencher D; McCormick C; ElNaggar AC; Altman AD; Gilbert L; Black D; Kabil N; Bennett J; Munley J; Aghajanian C
    Gynecol Oncol; 2022 Sep; 166(3):425-431. PubMed ID: 35803835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas.
    Yi T; Feng Y; Sundaram R; Tie Y; Zheng H; Qian Y; You D; Yi T; Wang P; Zhao X
    Int J Cancer; 2019 Sep; 145(5):1209-1220. PubMed ID: 30666631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of PARP Inhibitors as Maintenance Treatment on Restricted Mean Survival Time in Platinum-Sensitive Recurrent Ovarian Cancer: A Systematic Review and Meta-analysis.
    Kaneko M
    Ann Pharmacother; 2022 Jan; 56(1):27-34. PubMed ID: 33926263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical assays for assessment of homologous recombination DNA repair deficiency.
    Stover EH; Fuh K; Konstantinopoulos PA; Matulonis UA; Liu JF
    Gynecol Oncol; 2020 Dec; 159(3):887-898. PubMed ID: 33012552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.